全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

肝内胆管细胞癌合并肝门巨大淋巴结转移一例
Intrahepatic Cholangiocarcinoma with Huge Hilar Hepatic Lymph Node Metastasis: A Case Report

DOI: 10.12677/ACRS.2021.103007, PP. 45-50

Keywords: 肝内胆管细胞癌,肝门部淋巴结转移,外科手术,病例报道
Intrahepatic Cholangiocarcinoma
, Hilar Hepatic Lymph Node Metastasis, Surgical Operation,Case Reports

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:明确肝内胆管细胞癌合并淋巴结转移的患者行淋巴结清扫术的安全性以及可能获益。方法:分析1例原发性肝内胆管细胞癌合并巨大的肝门部淋巴结转移的中老年男性患者的临床表现、影像学表现、手术情况、术后并发症以及随访情况。结果:此例患者手术时间为315分钟,术中出血500 ml,术后住院时间8天,无术后主要并发症,该患者病理为中–低分化胆管细胞癌,肿瘤大小5 × 3.5 × 3 cm,8、12、13组淋巴结转移癌并融合肿块,目前随访8个月未见肿瘤复发。结论:肝内胆管细胞癌合并淋巴结转移的患者行淋巴结清扫术,手术风险可控,可能延长患者的无病生存期。
Objective: To determine the safety and potential benefit of lymph node dissection in patients with intrahepatic cholangiocellular carcinoma with lymph node metastasis. Methods: A case of primary intrahepatic cholangiocarcinoma with large hilar lymph node metastasis was analyzed, including the clinical manifestations, imaging manifestations, surgical status, postoperative complications and follow-up. Results: The operation time of this patient was 315 minutes, the intraoperative hemorrhage was 500 ml, the postoperative hospital stay was 8 days, and no major postoperative complications were observed. The patient was pathologically identified as moderately to poorly differentiated cholangiocarcinoma with tumor size of 5 × 3.5 × 3 cm, lymph node metastasis and mass fusion in group 8, 12, and 13, and no tumor recurrence was observed during 8 months of follow-up. Conclusion: Lymph node dissection in patients with intrahepatic cholangiocellular carcinoma with lymph node metastasis can control the risk of operation and may prolong the disease-free survival of patients.

References

[1]  Aljiffry, M., Abdulelah, A., Walsh, M., et al. (2009) Evidence Based Approach to Cholangiocarcinoma: A Systematic Review of the Current Literature. Journal of the American College of Surgeons, 208, 134-147.
https://doi.org/10.1016/j.jamcollsurg.2008.09.007
[2]  Shaib, Y.H., Davila, J.A., McGlynn, K., et al. (2004) Ris-ing Incidence of Intrahepatic Cholangiocarcinoma in the United States: A True Increase? Journal of Hepatology, 40, 472-477.
https://doi.org/10.1016/j.jhep.2003.11.030
[3]  Spolverato, G., Vitale, A., Cucchetti, A., et al. (2015) Can Hepatic Resection Provide a Long-Term Cure for Patients with Intrahepatic Cholangiocarcinoma? Cancer, 121, 3998-4006.
https://doi.org/10.1002/cncr.29619
[4]  Bridgewater, J., Galle, P.R., Khan, S.A., et al. (2014) Guide-lines for the Diagnosis and Management of Intrahepatic Cholangiocarcinoma. Journal of Hepatology, 260, 1268-1289.
https://doi.org/10.1016/j.jhep.2014.01.021
[5]  Hyder, O., Marques, H., et al. (2014) A Nomogram to Predict Long-Term Survival after Resection for Intrahepatic Cholangiocarcinoma: An Eastern and Western Experience. JAMA Surgery, 149, 432-438.
https://doi.org/10.1001/jamasurg.2013.5168
[6]  沈锋, 王葵, 阎振林, 等. 1370例肝内胆管细胞癌肝切除术的疗效及预后因素分析[J]. 中华消化外科杂志, 2016, 15(4): 319-328.
[7]  Zhou, R., Lu, D.H., et al. (2019) Is Lymph Node Dissection Necessary for Resectable Intrahepatic Cholangiocarcinoma? A Systematic Review and Meta-Analysis. HPB, 221, 784-792.
https://doi.org/10.1016/j.hpb.2018.12.011
[8]  Lee, A.J. and Chun, Y.S. (2018) Intrahepatic Cholangiocarcinoma: The AJCC/UICC 8th Edition Updates. Chinese Clinical Oncology, 7, 52.
https://doi.org/10.21037/cco.2018.07.03
[9]  Kim, S.H., Han, D.H., et al. (2019) Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: A Propensity Score-Matched Study. Journal of Gastrointestinal Surgery, 23, 538-544.
https://doi.org/10.1007/s11605-018-3899-2
[10]  黄志强. 3D时代的肝胆胰外科: 从“阿童木”到“阿凡达” [J]. 中华腔镜外科杂志(电子版), 2010, 3(3): 218-220.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133